Soluble type II transforming growth factor-β receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis

Molecular Cancer Therapeutics

Volumn 1, Issue 3, 2002, Pages 161-167

  Rowland Goldsmith, Melissa A ^a   Maruyama, Haruhisa ^a   Matsuda, Kei ^a   Idezawa, Takenao ^a   Ralli, Monica ^a   Ralli, Sonia ^a   Korc, Murray ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; UROKINASE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; METASTASIS; MOUSE; NORTHERN BLOTTING; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, NORTHERN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0036050857     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sporn, M. B., and Roberts, A. B. Transforming growth factor-β: recent progress and new challenges. J. Cell Biol., 119: 1017-1021, 1992.
2. Massagué, J. TGF-β signal transduction. Annu. Rev. Biochem., 67: 753-791, 1998.
3. Kingsley, D. M. The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev., 8: 133-146, 1994.
4. Gold, L. The role for transforming growth factor-β (TGF-β) in human cancer. Crit. Rev. Oncog., 10: 303-360, 1999. (Pubitemid 30058460)
5. Heldin, C-H., Miyazono, K., and tenDijke, K. TGF-β signalling from cell membrane to nucleus trough SMAD proteins. Nature (Lond.), 390: 465-471, 1997. (Pubitemid 28013118)
6. Massagué, J, and Chen, Y. G. Controlling TGF-β signaling. Genes Dev., 14: 627-644, 2000.
7. Derynck, R., Zhang, Y., and Feng, X. H. Smads: transcriptional activators of TGF-β responses. Cell, 95: 737-740, 1998. (Pubitemid 29014453)
8. Attisano, L., and Wrana, J. L. Smads as transcriptional co-modulators. Curr. Opin. Cell Biol., 12: 235-243, 2000. (Pubitemid 30142572)
9. Massagué, J., and Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J., 19: 1745-1754, 2000. (Pubitemid 30204386)
10. Warshaw, A. L, and Fernández del Castillo C. Pancreatic carcinoma. N. Engl. J. Med., 326: 455-465, 1992.
11. Friess, H., Yamanaka, Y., Büchler, M. W., Ebert, M., Beger, H. G., Gold, L. I., and Korc, M. Enhanced expression of transforming growth factor-β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105: 1846-1856, 1993. (Pubitemid 24002804)
12. Hahn, S. A., Schutte, M, Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash. DC), 271: 350-353, 1996.
13. Kleeff, J., Maruyama, H., Friess, H., Büchler, M. W., Falb, D., and Korc M. Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem. Biophys. Res. Commun., 255: 268-273, 1999. (Pubitemid 29292248)
14. Kleef, J., Ishiwata, T., Maruyama, H., Truong, P., Büchler, M. W., Falb, D., and Korc, M. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene, 18: 5363-5372, 1999. (Pubitemid 29469224)
15. Wagner, M., Kleeff, J., Lopez, M. E., Bockman, I., Massagué, J., and Korc, M. Transfection of the type I TGF-β receptor restores TGF-β responsiveness in pancreatic cancer. Int. J. Cancer, 78: 255-260, 1998. (Pubitemid 28443185)
16. Rowland-Goldsmith, M. A., Maruyama, H., Kusama, T., Ralli, S., Korc, M. Soluble type II transforming growth factor (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin. Cancer Res., 7: 2931-2940, 2001. (Pubitemid 32911404)
17. Baldwin, R. L., Friess, H., Yokoyama, M., Lopez, M. E., Kobrin, M. S., Büchler, M. W., and Korc, M. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int. J. Cancer, 67: 283-288, 1996. (Pubitemid 26274162)
18. Ellenrieder, V., Hendler, S. F., Ruhland, C., Boeck, W., Adler, G, and Gress, T. M. TGF-β-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int. J. Cancer, 93: 204-211, 2001. (Pubitemid 32574276)
19. Kleeff, J., Ishiwata, T., Kumbasar, A., Friess, H., Büchler, M. W., Lander, A. D., and Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Investig., 102: 1662-1673, 1998. (Pubitemid 28516251)
20. Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Büchler, M. W., and Beger, H. G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J. Clin. Investig., 90: 1352-1360, 1992.
21. Reyes, G., Villanueva, A., Garcia, C., Sancho, J., Piulats, J., Lluis, F., and Capella, G. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res., 56: 5713-5719, 1996. (Pubitemid 26422177)
22. Cantero, D, Friess, H, Deflorin, J, Zimmermann, A, Brundler, M. A., Riesle, E, Korc, M, and Büchler, M. W. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer, 75: 388-395, 1997. (Pubitemid 27051054)
23. Wang, W., Abbruzzese, J. L., Evans, D. B., and Chiao, P. J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene, 18: 4554-4563, 1999. (Pubitemid 29405887)
24. Kleeff, J., Friess, H., Simon, P., Susmallian, S., Büchler, P., Zimmermann, A., Büchler, M. W., and Korc M. Overexpression of Smad2 and colocalization with TGF-β1 in human pancreatic cancer. Dig. Dis. Sci., 44: 1793-1802, 1999. (Pubitemid 29446842)
25. Arrick, B. A., Lopez, A. R., Elfman, F., Ebner, R., Damsky, C. H., and Derynck, R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J. Cell Biol., 118: 715-726, 1992.
26. Arteaga, C. L, Carty, Dugger, T, Moses, H. L., Hurd, S. D., and Pietenpo, l J. A. Transforming growth factor β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ., 4: 193-201, 1993.
27. Bandyopadhyay, A., Zhu, Y., Cibull, M. L., Bao, L, Chen, C., and Sun, L. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res., 59: 5041-5046, 1999. (Pubitemid 29472913)
28. Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Wieser, R., Massagué, J., Mundy, G. R, and Guise T. A. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Investig., 103: 197-206, 1999. (Pubitemid 29053137)
29. Won, J., Kim, H., Park, E. J, Hong, Y., Kim, S. J., and Yun, Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res., 59: 1273-1277, 1999. (Pubitemid 29136258)
30. Portella, G., Cumming, S. A., Liddell, J, Cui, W., Ireland, H., Akhurst, R. J., and Balmain A. Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ., 9: 393-404, 1998. (Pubitemid 28345878)
31. Gutierrez, L. S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V. A., and Castellino, F. J. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res., 60: 5839-5847, 2000.
32. Munger, J. S., Harpe, J. G., Gleizes, P. E., Mazzieri, R., Nunes, I., and Rifkin, D. B. Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int., 51: 1376-1382, 1997. (Pubitemid 27239886)
33. Kojima, S., Nara, K., and Rifkin, D. B. Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Biol., 121: 439-448, 1993. (Pubitemid 23110886)
34. Haroon, Z. A., Hettasch, J. M., Lai, T. S., Dewhirst, M. W., and Greenberg, C. S. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J., 13: 1787-1795, 1999. (Pubitemid 29473340)
35. Mishima, K., Mazar, A. P., Gown, A., Skelly, M., Ji, X. D., Wang, X. D., Jones, T. R., Cavenee, W. K., and Huang, H. J. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. USA, 97: 8484-8489, 2000. (Pubitemid 30639699)
36. Ishiwata, T., Bergmann, U., Kornmann, M., Lopez, M., Beger, H. G., and Korc, M. Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas, 15: 367-373, 1997. (Pubitemid 27525632)
37. Elsasser, H. P., MacDonald, R., Dienst, M., and Kern, H. F. Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. Eur. J. Cell. Biol., 61: 321-328, 1993. (Pubitemid 23307544)
38. Kleeff, J., and Korc, M. Up-regulation of transforming growth factor (TGF)-β receptors by TGF-β1 in COLO-357 cells. J. Biol. Chem., 273: 7495-7500, 1998. (Pubitemid 28152773)
39. Andreasen, P. A., Egelund, R., and Peterson, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci., 57: 25-40, 2000. (Pubitemid 30105328)
40. Schwarte-Waldhoff, I., Klein, S., Blass-Kampmann, S., Hintelmann, A., Eilert, C., Dreschers, S., Kalthoff, H., Hahn, S. A., and Schmiegel, W. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene, 18: 3152-3158, 1999. (Pubitemid 29261236)